D. Boral Capital Initiates Coverage on Compass Therapeutics (NASDAQ:CMPX)

D. Boral Capital initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research report sent to investors on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

Several other analysts also recently commented on the stock. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research report on Monday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. Leerink Partners downgraded shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.80.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX traded up $0.13 during mid-day trading on Monday, reaching $1.51. The company had a trading volume of 361,647 shares, compared to its average volume of 438,909. The stock has a market capitalization of $207.76 million, a PE ratio of -4.08 and a beta of 0.89. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $2.34. The stock's 50 day moving average is $1.65 and its 200-day moving average is $1.41.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. On average, sell-side analysts anticipate that Compass Therapeutics will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Institutional investors have recently made changes to their positions in the business. Rovin Capital UT ADV bought a new stake in Compass Therapeutics during the 3rd quarter valued at approximately $25,000. Intech Investment Management LLC bought a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics in the third quarter worth $37,000. Cubist Systematic Strategies LLC bought a new position in Compass Therapeutics during the second quarter worth $41,000. Finally, Panagora Asset Management Inc. acquired a new position in Compass Therapeutics during the 2nd quarter valued at $68,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.